Roth Capital analyst Scott Henry raised his price target for Ligand Pharmaceuticals to $190 from $180 following yesterday’s analyst meeting. The company’s base business is better than expected, Henry tells investors in a research note. The analyst upped his 2020 revenue target to $126M from $118M and sees upside to Ligand’s targets based on milestones. He reiterates a Buy rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.